Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shirvan herbal ointment versus Glucantime for cutaneous leishmaniasis lesions
IRCT20230621058552N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Re-epithelialization of lesions and Average healing time of lesions. Started Aug 2023; status: completed.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20230621058552N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230621058552N1.